Last reviewed · How we verify
TK006
At a glance
| Generic name | TK006 |
|---|---|
| Also known as | fully human monoclonal anti-RANKL antibody |
| Sponsor | Jiangsu T-Mab Biopharma Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (PHASE2)
- Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (EARLY_PHASE1)
- Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases (PHASE1)
- Assessment of Anti-RANKL Antibody in Post-menopausal Women (PHASE1)
- Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TK006 CI brief — competitive landscape report
- TK006 updates RSS · CI watch RSS
- Jiangsu T-Mab Biopharma Co.,Ltd portfolio CI